CONFERENCE UPDATE: ASH 2020

APOLLO: Phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

27 Feb 2021

Get access to our exclusive articles.
Related Articles